ER-100 moves toward the next dose

# ER-100 moves toward the next dose OCTOBER 11, 2026 Life Biosciences says the first three people to receive its cellular reprogramming drug ER-100 tolerated it through Day 56, and two of them showed early gains on a standard vision test, according to the company's October 8, 2026 press release. The commercial significance of an early clinical program rests on what its next experiment can establish. For ER-100, the immediate step is dose escalation following the initial safety review. This article is based on that press release, which STAT also reported. The underlying study was not available as a paper, and the paper itself was not reviewed. According to the release, all three participants have open-angle glaucoma. Each received a single injection into the eye at the first dose level (2×10¹¹ vg), plus daily oral doxycycline. The doxycycline switches on three genes, OCT4, SOX2 and KLF4, known together as OSK. The company says these genes reset cells to a more youthful state. An oral prednisolone taper is given to limit inflammation from the viral vector. On safety, the release reports no dose-limiting toxicities, no adverse events of special interest and no serious adverse events. The company says every reported adverse event was related to the procedure, the steroid or a pre-existing condition, not to ER-100 itself. On vision, the release reports improvement on Humphrey visual field testing in two of the three participants at Day 56. In each, at least 28% of test points improved by more than 4 dB. The company calls these preliminary observations. It describes the trial as an open-label Phase 1 study designed to test safety and tolerability. The release describes no comparison group. The dose-escalation decision matters most for strategy, though it is a safety-review step, not a regulatory approval. According to the release, the Data Safety Monitoring Board, the trial's safety oversight group, recommended moving to Dose Level 2 (6×10¹¹ vg), and the trial is ongoing (NCT07290244). The company also lists non-arteritic anterior ischemic optic neuropathy (NAION) as a target. The release says no treatments are currently approved for it. The Phase 1 trial began in the first quarter of 2026. Our analysis: the release names no competitors and gives no financing details, so it cannot show where Life Bio stands against other developers. What it does show is a company-reported safety signal at the lowest dose, in three patients, over eight weeks. That is early. Any investor or rival will want to know whether the vision signals persist, whether they appear at higher doses, and whether a controlled study confirms them. The main limitation is the vision result: with three patients, no comparison group and an open-label design, it cannot be separated from chance or test variability. ER-100 is an investigational treatment, and this article is not medical advice. Readers should not start or stop any medication or treatment, including doxycycline or prednisolone, without consulting their clinician. Watch next for results from Dose Level 2 and for longer follow-up on the first three participants. The value of the platform will become clearer through repeated, interpretable observations. For now, the next cohort and longer follow-up are the milestones that count. Source: Life Biosciences (press release); also reported by STAT ---